- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
Patent holdings for IPC class A61K 38/48
Total number of patents in this class: 3951
10-year publication summary
361
|
351
|
395
|
402
|
351
|
392
|
342
|
349
|
283
|
156
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Allergan, Inc. | 2350 |
148 |
Ipsen Biopharm Limited | 262 |
68 |
MERZ PHARMA GmbH & CO. KGaA | 618 |
66 |
Talengen International Limited | 79 |
60 |
Revance Therapeutics, Inc. | 143 |
38 |
The Regents of the University of California | 19887 |
37 |
Baxter International Inc. | 2401 |
36 |
Modernatx, Inc. | 1259 |
36 |
Curemark, LLC | 79 |
35 |
Bioverativ Therapeutics Inc. | 215 |
34 |
The Children's Hospital of Philadelphia | 788 |
32 |
Translate bio, Inc. | 415 |
32 |
Baxter Healthcare S.A. | 1828 |
30 |
Penland Foundation | 39 |
30 |
HANSA Biopharma AB | 65 |
29 |
Takeda Pharmaceutical Company Limited | 2714 |
28 |
Omrix Biopharmaceuticals Ltd. | 153 |
26 |
Alexion Pharmaceuticals, Inc. | 634 |
25 |
Talengen Institute of Life Sciences Co., Ltd. | 28 |
25 |
Smith & Nephew, Inc. | 2682 |
24 |
Other owners | 3112 |